These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 11699313

  • 1. [Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors].
    Herkel U, Pfeiffer N.
    Ophthalmologe; 2001 Oct; 98(10):929-33. PubMed ID: 11699313
    [Abstract] [Full Text] [Related]

  • 2. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE, Friren B, International Brinzolamide Adjunctive Study Group.
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [Abstract] [Full Text] [Related]

  • 3. [Azarga, a new and useful fixed combination in glaucoma treatment].
    Călugăru M, Călugăru D.
    Oftalmologia; 2011 Aug; 55(3):38-46. PubMed ID: 22428291
    [Abstract] [Full Text] [Related]

  • 4. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Sezgin Akçay Bİ, Güney E, Bozkurt KT, Unlü C, Akçali G.
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH.
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [Abstract] [Full Text] [Related]

  • 6. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.
    Januleviciene I.
    Curr Med Res Opin; 2010 Nov; 26(11):2575-8. PubMed ID: 20868340
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy on intraocular pressure and retinal blood flow of a beta-blocker (timolol maleate) against the fixed association of a topical carbonic anhydrase (dorzolamide) and a beta-blocker (timolol maleate).
    Brogliatti B, Rolle T, Vizzeri GM, Cipullo D.
    Acta Ophthalmol Scand Suppl; 2000 Nov; (232):47-9. PubMed ID: 11235534
    [No Abstract] [Full Text] [Related]

  • 8. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
    Gugleta K.
    Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients.
    Martínez A, Sánchez-Salorio M.
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):239-48. PubMed ID: 19348600
    [Abstract] [Full Text] [Related]

  • 10. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.
    Croxtall JD, Scott LJ.
    Drugs Aging; 2009 Jun; 26(5):437-46. PubMed ID: 19552495
    [Abstract] [Full Text] [Related]

  • 11. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
    Heijl A, Strahlman E, Sverrisson T, Brinchman-Hansen O, Puustjärvi T, Tipping R.
    Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
    [Abstract] [Full Text] [Related]

  • 12. Fixed topical combinations in glaucomatous patients and ocular discomfort.
    Nebbioso M, Evangelista M, Librando A, Di Blasio D, Pescosolido N.
    Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
    [Abstract] [Full Text] [Related]

  • 13. Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma.
    D'Andrea A, D'Andrea D, Ferreri G.
    Acta Ophthalmol Scand Suppl; 1998 Sep; (227):36-8. PubMed ID: 9972339
    [Abstract] [Full Text] [Related]

  • 14. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF, Ochsner KI.
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [Abstract] [Full Text] [Related]

  • 15. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G, Denis P, Chew P, Sharpe ED, Orengo-Nania S, Coote MA, Laganovska G, Volksone L, Zeyen T, Filatori I, James J, Aung T.
    J Glaucoma; 2009 Feb; 18(4):293-300. PubMed ID: 19365194
    [Abstract] [Full Text] [Related]

  • 16. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
    Eichhorn M.
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J.
    Eur J Ophthalmol; 2000 Feb; 10(3):198-204. PubMed ID: 11071026
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
    Sugrue MF.
    Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
    [Abstract] [Full Text] [Related]

  • 19. Switching from dorzolamide to brinzolamide: effect on intraocular pressure and patient comfort.
    Inoue K, Wada SA, Wakakura M, Inoue J, Tomita G.
    Jpn J Ophthalmol; 2006 Jan; 50(1):68-9. PubMed ID: 16453193
    [No Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.